Molecular Dissection Of Aberrant IL6/gp130 And TGF? Signaling In The Pathogenesis Of Interstitial Pneumonitis
Funder
National Health and Medical Research Council
Funding Amount
$590,009.00
Summary
Interstitial pneumonia (IP) is frequently observed in the group of lung diseases which affect the transfer of oxygen from inhaled air into the bloodstream. Current treatments for these diseases only effectively manage patient’s symptoms but don’t cure patients of IP. We have developed a strategy to identify the exact cell type responsible for an acute IP and the molecular intermediates that may offer novel treatments and pave the way for a possible cure for this disease.
Investigation Into The Roles Of Ena/VASP-Like And Protein Phosphatase 4C In DNA Damage Repair Via Homologous Recombination
Funder
National Health and Medical Research Council
Funding Amount
$57,139.00
Summary
The repair of DNA damage is a critical cellular mechanism that exists to ensure genomic stability. This project aims to investigate the role of the proteins Ena/VASP-Like and Protein Phosphatase 4C in DNA damage repair via homologous recombination. The DNA damage response pathway is an important area in the study of cancer and ageing, and the potential role of PP4C and EVL in homologous recombination needs to be investigated further.
Role Of Oxidative Stress In Activating ATM To Protect Against Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$570,334.00
Summary
ATM is the protein defective in the human genetic disorder ataxia-telangiectasia (A-T). This project is designed to investigate how this protein is activated by oxidative stress. The study is largely a mechanistic one, to investigate changes occurring in ATM as part of the activation process. There is evidence that ATM exists in the cytoplasm in neuronal cells and understanding its function in these cells may assist in understanding the basis for neurodegeneration in A-T.
The overall goal of the program is to develop novel approaches to slow the progress or prevent neurodegeneration in patients with rare human genetic disorders. The second program is designed to develop novel therapeutics from snake venom proteins. These include proteins with anti-bleeding activity and those with application in wound healing. The third program involves the development of novel biomarkers for the early detection and prognosis in prostate cancer.